Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
Najia, Mohamad , Jha, Deepak Kumar , Zhang, Cheng , Kubaczka, Caroline , Markel, Arianna , Li, Christopher , Morris, Vivian Gunn, Tompkins, Allison, Hensch, Luca, Qin, Yue , Huang, Yu-Chung , Marunde, Matthew R. , Vaidya, Anup , Gillespie, Zachary B , Shi, Yang , Li, Hu , Daley, George Q. , Najia, Mohamad Ali , Jha, Deepak K , North, Trista E , Keogh, Michael-Christopher , Schlaeger, Thorsten M , Shipp, Margaret Ann , Blainey, Paul C , Daley, George Q , Laurent, Benoît , Li, Christopher, Morris, Vivian, Chapuy, Bjoern , Morse, Michael, Howard, Sarah A. , Domínguez, Daniel

Mayo Clinic

No container title available | February 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.31.635709 | PMID 39975048 Get It

ABSTRACT Genes involved in the regulation of chromatin structure are frequently disrupted in cancer, contributing to an aberrant transcriptome and phenotypic plasticity. Yet, therapeutics targeting mutant forms of chromatin-modifying enzymes have yielded only modest clinical utility, underscoring the difficulty of targeting the epigenomic underpinnings of aberrant gene regulatory networks. Here, we sought to identify novel epigenetic vulnerabilities in diffuse large B-cell lymphoma (DLBCL). Through phenotypic screens and biochemical analysis, we demonstrated that inhibition of the H3K9 demethylases KDM4A and KDM4C elicits potent, subtype-agnostic cytotoxicity by antagonizing transcriptional networks associated with B-cell identity and epigenetically rewiring heterochromatin. KDM4 demethylases associated with the KRAB zinc finger ZNF587, and their enzymatic inhibition led to DNA replication stress and DNA damage-induced cGAS-STING activation. Broad surveys of transcriptional data from patients also revealed KDM4 family dysregulation in several other cancer types. To explore this potential therapeutic avenue, we performed high-throughput small molecule screens with H3K9me3 nucleosome substrates and identified novel KDM4 demethylase inhibitors. AI-guided protein-ligand binding predictions suggested diverse modes of action for various small molecule hits. Our findings underscore the relevance of targeting fundamental transcriptional and epigenetic mechanisms for anti-cancer therapy. HIGHLIGHTS Phenotypic screens identified JIB-04 as a potent anti-cancer agent for multiple subtypes of diffuse large B-cell lymphoma JIB-04 binds and inhibits KDM4 demethylases resulting in epigenomic rewiring of heterochromatin KDM4 demethylases cooperate with KRAB zinc fingers to limit DNA replication stress, and KDM4 inhibition instigates DNA-damage and cGAS-STING activation in several human cancers High-throughput small molecule screens with semi-synthetic nucleosome substrates and AI-guided molecular docking simulations identify novel KDM4 inhibitors
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, Haiyan , Marsh, Thomas W. , Shi, Xinyu , Bowling, Kevin M. , Ziegemeier, Ellen , Wang, Guoqiao , Cao, Yuchen , Aristel, Alisha, Li, Jessie, Dickson, Alexa , Perrin, Richard J. , Goate, Alison , Fernández, María Victoria , Day, Gregory S. , Doering, Michelle , Daniels, Alisha , Hassenstab, Jason , Supnet, Charlene , Xiong, Chengjie , Berman, Sarah , Ryan, Natalie S. , Huey, Edward D. , Noble, James M. , Roh, Jee Hoon , Laske, Christoph , Sánchez‐Valle, Raquel , Méndez, Patricio Chrem, Chhatwal, Jasmeer P. , Farlow, Martin R. , Xiong, Chengjie , Gordon, Brian A , Ibanez, Laura , Vöglein, Jonathan , Roh, Jee Hoon , Ikeuchi, T , Sánchez-Valle, Raquel , Chhatwal, Jasmeer , Xiong, Chengjie , Rosa-Neto, Pedro , Schofield, Peter R , Bateman, Randall J , Cruchaga, Carlos , Day, Gregory S , Hassenstab, Jason , Fernandez, Maria , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Renton, Alan , Gordon, Brian A. , Benzinger, Tammie L.S. , Allegri, Ricardo , Fox, Nick C. , Vöglein, Jonathan , Jucker, Mathias , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Levey, Allan I. , Lopera, Francisco Javier , Martins, Ralph N. , Niimi, Yoshiki , Bateman, Randall J. , Karch, Celeste M. , McDade, Eric , Llibre‐Guerra, Jorge J.

Mayo Clinic

Brain | February 4, 2025 | Volume: 148 | Issue: 7 | Pages: 2429-2440

10.1093/brain/awaf038 | PMID 39903689 Get It

Abstract We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer’s disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.
Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid, Tabinda , Elbarougy, Doaa E. , Lavu, Sravanthi , Buia, Guillaume, Senum, Sarah R. , Olinger, Eric , Yang, Hana , Bublitz, Joshua T., Ma, Jun , Audrézet, Marie‐Pierre , Madsen, Charles D. , Schauer, R., Baker, Tracy A. , Gregory, Adriana , Orr, Sarah , Barroso‐Gil, Miguel , Neatu, Ruxandra , Joli, Giancarlo, Dahl, Neera K. , Kline, Timothy L. , Jouret, François , Steinman, Theodore I., Watnick, Terry , Larson, Nicholas B. , Halbritter, Jan , Harris, Peter C. , Gastel, Maatje D.A. van , Jawaid, Tabinda , Ma, Jun , Audrézet, Marie-Pierre , Madsen, Charles D , Schauer, Rachel S , Baker, Tracy A , Gregory, Adriana V , Orr, Sarah E , Barroso-Gil, Miguel , Neatu, Ruxandra , Dahl, Neera K , Kline, Timothy L , Gillion, Valentine , Jouret, Francois , Torres, Vicente E , Peters, Dorien J M , Gitomer, Berenice Y , Watnick, Terry J , Chebib, Fouad T , Hogan, Marie C , Olson, Janet E , Larson, Nicholas B , Ars, Elisabet , Halbritter, Jan , Demoulin, Nathalie , Torres, Vicente E , Sayer, John A , Cornec-Le Gall, Emilie , Harris, Peter C , Senum, Sarah R , Elbarougy, Doaa E , Buia, Guillaume, McDonnell, Shannon K. , Dahan, Karin , Perrone, Ronald D. , Peters, Dorien J.M. , Coto, Eliécer , Chebib, Fouad T. , Hogan, Marie C. , Olson, Janet E. , Torres, Vicente E. , Gall, Émilie Cornec-Le

Mayo Clinic

Journal of the American Society of Nephrology | February 3, 2025 | Volume: 36 | Issue: 6 | Pages: 1056-1071

10.1681/asn.0000000613 | PMID 39899384 Get It

Key Points Loss-of-function ALG8 and ALG9 variants were enriched in polycystic kidney/liver groups and International Classification of Diseases–coded cystic individuals in population cohorts. The ALG8 and ALG9 kidney phenotypes were usually mild to moderate, and lower eGFR or kidney failure was rare. ALG8 pathogenic variants sometimes resulted in severe polycystic liver disease. Background Autosomal dominant polycystic kidney disease (ADPKD) is a common, inherited nephropathy often resulting in kidney failure. It is genetically heterogeneous; along with the major genes, PKD1 and PKD2 , at least eight others have been suggested. ALG8 pathogenic variants have been associated with autosomal dominant polycystic liver disease and implicated in ADPKD, while ALG9 has been suggested as an ADPKD gene, but details of the phenotypes and penetrance are unclear. Methods We screened >3900 families with cystic kidneys and/or livers using global approaches to detect ALG8 or ALG9 pathogenic variants. In addition, population cohorts with sequence data (Genomics England 100K Genomics Project, UK Biobank, and Mayo Clinic Biobank [MCBB]) were screened for ALG8 / ALG9 pathogenic variants. Results Multicenter screening of individuals with polycystic kidney and/or liver disease identified 51 (1.3%) ALG8 (7 multiplex) and 23 (0.6%) ALG9 (5 multiplex) families—frequencies that were approximately 10× and approximately 24× greater than nonpolycystic kidney disease controls. Analysis of individuals with polycystic kidney disease phenotypes in 100K Genomics Project, UK Biobank, and MCBB identified nine ALG8 (0.39%) and nine ALG9 (0.39%) families, an enriched frequency over controls. Two individuals had PKD1 and ALG8 pathogenic changes. Eighty-nine percent of individuals with ALG8 mutations with imaging in the entire MCBB had kidney cysts (50%, >10 cysts), with greater median kidney and liver cyst numbers than controls. For ALG9, 78% had kidney cysts (27%, >10 cysts). Individuals with ALG8 mutations typically had mild cystic kidneys with limited enlargement. Liver cysts were common (71%), with enlarged livers (>2L) found in 11 of 62 patients, although surgical intervention was rare. The ALG9 kidney phenotype was also of mild cystic kidneys, but enlarged livers were rare; for both genes, CKD or kidney failure were rare. Conclusions ALG8 and ALG9 are defined as cystic kidney/liver genes but with limited penetrance for lower eGFR.
Abstract A015: A prospective cohort study of biological aging and epigenetic age acceleration in 106 patients with age and therapy-related clonal hematopoiesis
Li, Marissa , Chandra, Tamir , Aug, Sarah, Lasho, Terra, Finke, Christy M. , Foran, James M. , Yi, Cecilia Y. Arana , Kusne, Yael , Mangaonkar, Abhishek A. , Gangat, Naseema , Simon, Rachel, Patnaik, Mrinal M. , Fernandez, Jenna , Kirschner, Kristina , McCullough, Kristen , Lasho, Terra, Yi, Cecilia Arana , Badar, Talha , Simon, Rachel, Ferrer, Alejandro

Mayo Clinic

Cancer Research | February 1, 2025 | Volume: 85 | Issue: 3_Supplement | Pages: A015-A015

10.1158/1538-7445.dnamethylation-a015 Get It

Abstract Background: Age-related clonal hematopoiesis (ARCH) is a precursor state to blood cancers and is associated with epigenetic age acceleration (EpiAgeAccel). While ARCH is associated with increased all-cause mortality and cardiovascular disease, not much is known about these risks with therapy-related clonal hematopoiesis (t-CH) – CH occurring in the context of prior cytotoxic chemotherapy/radiation exposure. Methods: Patients were prospectively recruited for CH and EpiAge assessment from Mayo Clinic between 2022 and 2024. CH status was determined using error corrected sequencing on peripheral blood (PB) DNA (sensitivity 0.5% VAF). Patients with CH were classified as t-CH if they had received chemotherapy or radiation prior to CH detection. All other CH cases were classifed as ARCH. For EpiAge analysis, PB DNA was analyzed using the Illumina MethylationEPIC array. The resulting beta values were used to obtain epigentic age estimates using Horvath’s clock, Hannum’s Clock, PhenoAge, DunedinPACE, and estimated telomere lengths (DNAmTL). Results: 106 (62%) of 170 patients assessed were found to have CH. CH patients were classified into ARCH-63 (59%) and t-CH-43 (41%). While the median chronological age (69 vs 67 years) was similar between ARCH and t-CH, t-CH patients had lower Hgb [10.9g/dL vs. 13g/dL (p=0.0001)], lower platelet [146x109/L vs. 192x109/L (p=0.0132)] and lower WBC [4.4x109/L vs. 5.2x109/L (p=0.0345)]. The 3 most common ARCH mutations were TET2 (20%), DNMT3A (19%), and ASXL1 (14%), while PPM1D (27%), TET2 (18%), and DNMT3A (14%) were most frequent in t-CH. There was no significant difference in median EpiAge via Horvath (68 vs 67.5years p=0.2826), Hannum (65 vs 66 years p=0.9333), or PhenoAge (55 vs 56 years p=0.618) between ARCH and t-CH. However, DunedinPACE of aging was higher in t-CH (1.27 vs 1.18 bioyear/chronoyear p=0.0148) and median DNAmTL was shorter in t-CH (6.35 vs 6.49kb p=0.0247), compared to ARCH (Note patients with telomere biology disorders were excluded). Multivariable regression analysis adjusting for chronologic age, smoking status, and male sex showed that both ARCH and t-CH had EpiAgeAccel via Horvath(5.8years p=0.0001, 3.4 years p=0.051), Hannum(5years p=0.001, 4.5 years p=0.007), and PhenoAge (6.7years p=0.002, 7.6 years p=0.002) clocks. t-CH more than doubled DunedinPACE (0.2 bioyear/chronoyear, p<0.001) of aging compared to ARCH (0.08 bioyear/chronoyear, p=0.026). t-CH also demonstrated a significant decrease in DNAmTL (0.34kb, p<0.001) in comparison to ARCH (0.17kb, p=0.015). With a median follow-up of 20 months, t-CH was associated with worse overall survival in comparison to ARCH, and non-CH patients (p=0.013, 93% vs. 90% alive at 10 months, 87 vs. 72% alive at 20 months). Conclusion: Our prospective CH cohort study validates the association between CH and EpiAgeAccel using several different methylation clocks and for the first time highlights an increased pace of aging and shorter DNAmTL in the context of inferior survival outcomes in t-CH. Citation Format: Marissa Li, Jenna Fernandez, Kristina Kirschner, Tamir Chandra, Kristen McCullough, Sarah Aug, Terra Lasho, Christy Finke, James Foran, Cecilia Arana Yi, Yael Kusne, Talha Badar, Abhishek Mangaonkar, Naseema Gangat, Rachel Simon, Alejandro Ferrer, Mrinal Patnaik. A prospective cohort study of biological aging and epigenetic age acceleration in 106 patients with age and therapy-related clonal hematopoiesis [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer; 2025 Feb 1-4; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2025;85(3 Suppl):Abstract nr A015.
483: PREDICTIVE PERFORMANCE OF EARLY WARNING SCORING SYSTEMS FOR ICU TRANSFER FOLLOWING CAR-T THERAPY
Pareek, Aayushi , Jena, Anek , Jonna, Sadhana , Raavi, Lekhya , Ayala, Ernesto , Heras, Marcos Las , Stefano, Sabrina Di , Lin, Yi, Sarah, Nix, Shapiro, Anna B, Kharfan‐Dabaja, Mohamed A. , Sanghavi, Devang , Huespe, Iván , Isha, Shahin , Iqbal, Madiha , Roy, Vivek , Parrondo, Ricardo D , Ailawadhi, Sikander , Murthy, Hemant S. , Franco, Pablo Moreno

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001100596.58924.19 Get It

219: RELIABILITY OF SYSTEMIC ANTICOAGULANTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION
Wieruszewski, Patrick M. , Brinkman, Hannah, Seelhammer, Troy G. , Damico, Katharine, Normand, Sarah , Gerberi, Dana , Wieruszewski, Erin D. , Wieruszewski, Patrick M

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001099540.44982.53 Get It

Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
González, Raul S. , Horton, Rachel K. , Zhang, Xuchen , Graham, Rondell P. , Longacre, Teri A. , Mehrotra, Anupamjit K., Allende, Daniela , McHugh, Kelsey , Shia, Jinru , Westerhoff, Maria , Chen, Wei , Vazzano, Jennifer , Cheema, Hassam, Ma, Changqing , Mannan, Abul Ala Syed Rifat , Agostini‐Vulaj, Diana , Kazemimood, Rossana , Henn, Patrick, Kakar, Sanjay , Choi, Won‐Tak , Adeyi, Oyedele , Allende, Daniela S , McHugh, Kelsey E , Srivastava, Amitabh , Chen, Wei , Vazzano, Jennifer , Swanson, Paul E , Ma, Changqing , Mannan, Abul A S R , Chetty, Runjan , Serra, Stefano , Agostini-Vulaj, Diana , Kazemimood, Rossana , Choi, Won-Tak , Adeyi, Oyedele , Jenkins, Sarah M. , Nagtegaal, Iris D , Gonzalez, Raul S , Graham, Rondell P , Srivastava, Amitabh , Chatterjee, Deyali , Nowak, Klaudia , Kakar, Sanjay , Jenkins, Sarah M, Nagtegaal, Irıs D.

Mayo Clinic

Histopathology | January 31, 2025 | Volume: 86 | Issue: 7 | Pages: 1064-1081

10.1111/his.15412 | PMID 39887413 Get It

AimsWe compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta‐analysis of cohorts and individual case series.Methods and ResultsWe identified 53 colorectal ASC from 19 North American academic medical centres, in addition to national database reports on 94 Dutch cases. We analysed available clinical, histologic, and immunohistochemical features and patient outcome. ASC comprised 0.02% of colorectal cancers in the Dutch database. The median cohort patient ages at resection were 65 and 69 years (North American and Dutch cohorts, respectively), with a roughly equal male:female ratio. The squamous component represented between 5% and 95% of each tumour, with a median of 50%. Tumour‐infiltrating lymphocytes (TILs) were generally low (66%), and tumour budding was often Bd1 (64%). Most cases were pT3 (55%) or pT4 (40%), with nodal metastases in more than half (58%). Twenty‐three cases (43%) metastasized distantly, most commonly to the liver. Mismatch repair (MMR) deficiency was identified in 34% of the cases. Follow‐up was available for 48 patients; 13 (27%) had recurrent disease and 29 (60%) died. A total of 31 patients progressed, with median time to progression of 18 months. Available data for the Dutch cohort revealed largely similar findings, as did review of cases in the literature.ConclusionColorectal ASC usually presents at an advanced stage. Despite high rates of MMR deficiency and low tumour budding, TILs were generally low, and there is a high recurrence rate and poor prognosis.
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Jacobson, Caron A. , Nikiforow, Sarah , Ahmed, Sairah , Miklos, David B. , Lin, Yi , Lunning, Matthew A. , Hill, Brian T. , Ghobadi, Armin , Hu, Zhen‐Huan , Hemmer, Michael, Zoratti, Michael J. , Vunnum, Suresh, Tsang, Jonathan , Spooner, Clare, Smith, Harry , Fu, Christine, Patel, Anik R. , Miao, Harry , Shahani, Shilpa, Mirjah, Debbie L., Xu, Hairong , Pasquini, Marcelo C. , Ahmed, Sairah , Miklos, David B , Ghobadi, Armin , Zoratti, Michael J , Pasquini, Marcelo , Locke, Frederick L. , Siddiqi, Tanya

Mayo Clinic

Blood Advances | January 30, 2025 | Volume: 9 | Issue: 11 | Pages: 2663-2676

10.1182/bloodadvances.2024013656 | PMID 39883946 Get It

Abstract Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel. The impact of V2Vt (<28 days vs ≥28 to <40 days vs ≥40 days) on effectiveness and safety outcomes was evaluated in patients treated with axi-cel enrolled in a post-authorization safety study using the Center for International Blood and Marrow Transplant Research data. SLR and meta-analysis showed that patients treated with axi-cel had the shortest median V2Vt (30.6 days) compared with tisa-cel (48.4 days) or liso-cel (35.9 days). Real-world analysis of patients treated with axi-cel demonstrated that V2Vt ≥40 days was associated with significantly lower complete response rate than V2Vt <28 days (odds ratio [OR], 0.61) or ≥28 to <40 days (OR, 0.66) and significantly worse overall survival than V2Vt <28 days (hazard ratio [HR], 1.33) or ≥28 to <40 days (HR, 1.36). Higher prolonged thrombocytopenia rates were observed in patients with axi-cel V2Vt ≥28 to <40 days or ≥40 days compared with <28 days (OR, 1.44 or 1.95, respectively). Together, these results show the impact of V2Vt on patient outcomes with axi-cel therapy and that earlier infusion with CD19-CAR therapies may be beneficial.
159. Transplant Transmitted Infectious Among Recipients of Drowned Donor Organs: A Six Year DTAC Experience
Miller, Rachel A. , Lee, Dong Heun , Te, Helen S. , Hughart, Anna L., Danziger‐Isakov, Lara , Fisher, Cynthia E. , Handarova, Dzhuliyana, Graves, Riki, Kittleson, M. , Marboe, Charles C. , Sellers, Marty T. , Taimur, Sarah , Sharma, Tanvi S , Watkins, T. I., Miller, Rachel A, Abidi, Maheen Z. , Berry, Gerald J. , Ho, Chak‐Sum , Trindade, Anil J , Wood, R Patrick, Zaffiri, Lorenzo , Watkins, Tamika, Pouch, Stephanie M.

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.045 Get It

Abstract Background Characterization of transplant transmitted infections associated with drowned organ donors and the recipients is not well delineated, posing challenges for optimal management and prophylaxis strategies. Broader organ sharing may pose additional considerations due to pathogen variation. Methods We reviewed 22 potential donor disease transmission events (PDDTEs) from drowned donors reported to the Organ Procurement and Transplantation Network (OPTN) ad hoc Disease Transmission Advisory Committee (DTAC) from 2017-2022 to estimate the incidence of PDDTEs among all US drowned organ donors and identify the most common pathogens in this setting. We also characterized donor/recipient epidemiology, infection timing and risk factors, and recipient survival. Results From 2017-2022, drowning was the mechanism of death in 777/74,232 (1.0%) of all US organ donors, from whom 2500 organs were transplanted. Among the 22 PDDTEs, there were 70 organ recipients. The median donor age was 17.5 years (range 1-70 years) and lung recipients accounted for 5/70 organ recipients. All PDDTE reports were submitted due to recipient disease, and index cases occurred 2-19 days post-transplant. 7/22 (7/777 drowned donors, 0.9%) PDDTEs were associated with pathogens consistent with plausible waterborne transmission, of which 4 were due to invasive molds (Zygomycetes and Scedosporium) and 3 were due to bacteria (Pseudomonas and Legionella). Of the 21 organ recipients from these 7 donors, 8 had proven or probable infections. 6/8 recipients had severe infection with 3 deaths, all from invasive mold infections. There were no identifiable infection risk factors related to drowning water source, donor immersion time, or geographic region. However, donor/recipient regional discordance occurred in 5/21 recipients, demonstrating the trend in broader organ sharing. Conclusion Though rare, organ recipients are at risk for transplant transmitted infection from drowned donors, particularly invasive mold infections. All infections occurred within the first month after transplant with high associated mortality. Though optimal management and prophylaxis strategies in these scenarios remain uncertain, post-transplant vigilance for early infection is paramount. Disclosures Helen S. Te, MD, CVS Caremark: Advisor/Consultant Lara A. Danziger-Isakov, MD, MPH, Aicuris: clinical research contract, paid to institutio|Ansun BioPharma: clinical research contract, paid to institution|Astellas: Advisor/Consultant|Astellas: clinical research contract, paid to institutio|Merck: clinical research contract, paid to institutio|Pfizer: Grant/Research Support|Takeda: clinical research contract, paid to institutio Anil J. Trindade, MD, CareDx, Inc.: Advisor/Consultant|CareDx, Inc.: Grant/Research Support|TFF Pharmaceuticals: Advisor/Consultant|Veloxis Pharmaceuticals, Inc.: Grant/Research Support
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
Zakharia, Yousef , Reis, Ryan J. , Kroll, Matthew R. , Rataan, Aseel O. , Manchkanti, Srija , Rahim, Bilal , Garje, Rohan , Swami, Umang , Mott, Sarah L. , Zamba, K.D. , Sieren, Jessica C. , Rustum, Youcef M. , Zamba, K D , Salem, Aliasger K , Rustum, Youcef , Garje, Rohan , Zakharia, Yousef , Salem, Aliasger K.

Mayo Clinic

Clinical Cancer Research | January 29, 2025 | Volume: 31 | Issue: 7 | Pages: 1204-1211

10.1158/1078-0432.ccr-24-3234 | PMID 39879383 Get It

Abstract Purpose: Data on clear-cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of hypoxia-inducible factor-1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC. Patients and Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment). Escalating dose levels of SLM (2,500, 3,000, and 4,000 μg) were administered orally twice daily for 14 days and then once daily concurrently with axitinib 5 mg twice daily using a 3 + 3 design in phase I. Patients were treated at the 4,000 μg dose level in the expansion cohort to obtain preliminary estimates of efficacy. Results: No dose-limiting toxicities occurred at the 4,000 μg SLM dose level. Among the 27 patients treated with 4,000 μg of SLM, the overall response rate was 55.6%, median duration of response was 18.4 months, median progression-free survival was 14.8 months, and median overall survival was 19.6 months. Preliminary results have shown that plasma selenium concentrations, inhibition of TGF-β1, and stabilization of tumor vasculature by SLM are time dependent. Conclusions: SLM (4,000 μg) in sequential combination with axitinib is well tolerated with encouraging efficacy.